Top Back to top

Physicians Webinars

Upcoming webinars from EBMT

PK and AntigenTarget differences of variant ATGs

REGISTRATION OPEN!

Register now to this live webinar on 15 June, from 16:00 to 17:00 CEST, click HERE and complete the webform.


The webinar will be hosted by Dr Jaap Jan Boelens and moderated by Dr Selim Corbacioglu.

Learning objectives:

  • When dosed weight based rATG pharmacokinetics is highly variable and results in highly unpredictable outcomes.
  • By individualizing rATG dosing, by considering the ALC prior to rATG dosing you can better predict immune reconstitution and subsequently survival.

Past webinars

  

The injured lung in HSCT – the nowadays diagnostic and therapeutic challenges

This webinar was organized by the Paediatric Diseases Working Party (PDWP).

Speaker: Tayfun Güngör. Moderator: Marianne Ifversen

On the basis of case studies from Zurich and Copenhagen exemplary pulmonary complications after allogeneic HSCT are described. The differential diagnostic considerations, diagnostic measures and therapies applied are presented and discussed in the context of the existing literature and guidelines. Preventive measures as well as ways to avoid lung complications after allogeneic HSCT are described. The webinar`s content might be helpful to improve communication between HSCT and ICU physicians regarding prognosis of pulmonary complications in HSCT patients.

Learning objectives:

  • Common patterns of pulmonary deterioration during and shortly after HSCT.
  • Reasonable, quick, and secure diagnostics.
  • Measures to prevent ICU transfer.
  • Treatment options on the ventilator.
  • Indication of ECMO.
  • Feasibility of HSCT on the ventilator.

State of the Art Lecture: Treatment of relapsed/refraction DLBCL in 2022

This webinar was hosted by Dr Georg Lenz and moderated by Dr Norbert Schmitz. It focused on the treatment options of patients with relapsed/refractory diffuse large B-cell lymphoma.

After the webinar, participants should be able to understand:

•    Different treatment options of patients with relapsed/refractory diffuse large B-cell lymphoma. 

Panel Discussion: Auto, Allo or CART in Mantle Cell Lymphoma

This webinar was the first edition of the Panel Discussion, the new format consists of presenting a topic in 10 minutes followed by a 20 min panel discussion. The host was Dr Martin Dreyling and the invited experts were Dr Anna Sureda and Dr Sascha Dietrich.

After the webinar, participants should be able to understand:

  • The heterogeneity of MCL and identify the different risk groups based on biological markers.
  • The role of autologous transplantation as part of standard first line therapy in young patients.
  • The potential of CAR-T cells in BTKi pretreated patients.
  • The potentially curative approach of allogeneic transplantation in the therapeutic algorithm of MCL.

Practice changing Paper: Eltrombopag added to immunosuppression in SAA (NEJM 2022)

This was the first edition of the Practice changing Paper, the new format consists of presenting a recently published paper in 10 minutes followed by a 20 min panel discussion.

The RACE trial is a practice changing study for all patients suffering from severe aplastic anaemia involving 24 EBMT sites in 6 countries. 

Speaker:

  • Régis Peffault de Latour. Full professor of hematology, head of the BMT Department in Saint-Louis Hospital and of the French Reference Center for Aplastic Anemia and PNH, Paris Cité University, Assistance Publique Hôpitaux de Paris, Paris, France.

Panel experts:

  • Antonio M Risitano. Head of Hematology and BMT Unit. AORN S. Giuseppe Moscati, Avellino. Professor of Hematology, Federico II University, Naples, Italy.
  • Professor Andrea Bacigalupo, Department of Hematology. Fondazione Policlinico Universitario A.Gemelli IRCCS Universita’ Cattolica del Sacro Cuore. Rome, Italy.
  • Phillip Scheinberg, MD. Hospital A Beneficência Portuguesa, São Paulo, Brazil.

Past workshops

Statistical Course - 2021 Edition

Basic course in the use of statistical methods to analyse stem cell transplantation data.

It had two parts:

  1. Collection of data, simple comparative analyses. Speaker: Richard Szydlo.

The first session covered the following topics:

  • Best data collection practices using Excel and Access
  • Basic descriptive and comparative statistical methods using a live analysis of data (with SPSS)
  • Optimum methods for collecting data that require statistical analysis
  • A review of the most commonly used statistical methods to describe and compare groups
  1. Essential survival analysis methods. Speaker: Antonella Santucci. 

The second session covered the following topics:

  • Interval Time of follow-up and the status variable (censored/event observations)
  • How to collect data 
  • The survival function
  • Kaplan-Meier curves and the log rank test
  • An introduction to Cox proportional hazard model
  • Demonstrative exercises will be done by  using SPSS vers.25.
IMPORTANT INFORMATION:

One week before the event, all participants received access to on-demand content regarding theoretical information of “Essential survival analysis methods”. During the live event, more practical aspects were explained and there was time for questions and answers.

On-demand material and attendance certificate is available to consult for registered participants on the e-learning platform. 

Speakers:

  • Dr Richard Szydlo, Medical Statistician, Department of Haematology, Imperial College, London, UK.
  • Dr Antonella SantucciHaemathology Institut University of Study of Perugia.

EBMT Benchmarking: The What, How and When?

The EBMT Clinical Outcomes Group (COG) has developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. In November 2020, centres received the first data-completeness reports. This webinar will explain the origins and methodology of the model, the centre perspective and the next steps. The webinar will be an opportunity for users to address questions to the expert panel and to give feedback on this first report. This feedback will be taken into account for the next phase of this project.

Learning Objectives:
  • Understand the basis of the benchmarking model

  • Learn to interpret the data-completeness report

  • Hear of future plans for the model

Speaker panel:

Chair: 

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.

Speakers: 

  • Prof. Dr. Hein Putter. Biostatistician, Leiden University Medical Center, Leiden, The Netherlands.

  • Riccardo Saccardi, MD. Director, Cell Therapy and Transfusion Medicine Unit. Careggi University Hospital, Firenze, Italy.

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.

Q&A Section: 

  • Prof. Dr. Hein Putter. Biostatistician, Leiden University Medical Center, Leiden, The Netherlands.

  • Riccardo Saccardi, MD. Director, Cell Therapy and Transfusion Medicine Unit. Careggi University Hospital, Firenze, Italy.

  • Professor John Snowden, Consultant Haematologist and Director of BMT, Sheffield Teaching Hospitals NHS Foundation Trust & University of Sheffield, UK.
  • Dirk-Jan Eikema. Biostatistician specialized in survival analysis. EBMT.

  • Isabel Sánchez-Ortega. Medical Officer. EBMT

Sponsorship

There are various opportunities to support the EBMT Educational Webinars. For more information, please send an email to fundraising@ebmt.org